|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with high lipoprotein(a) levels are at increased risk for AVS.
|
24704946 |
2014 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?
|
25340480 |
2014 |
|
Aortic Valve Stenosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of lipoprotein(a) were not causally associated with increased low-grade inflammation as measured through CRP despite a causal association with increased risk of aortic valve stenosis and MI.
|
25938632 |
2015 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Elevated lipoprotein(a) levels represent a genetically determined risk factor for myocardial infarction (MI) and aortic valve stenosis (AVS).
|
26656145 |
2016 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Elevated lipoprotein(a) (Lp[a]) is a highly prevalent (around 20% of people) genetic risk factor for cardiovascular disease and calcific aortic valve stenosis, but no approved specific therapy exists to substantially lower Lp(a) concentrations.
|
27665230 |
2016 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Elevated plasma concentrations of lipoprotein(a) (Lp(a)) are an independent and causal risk factor for cardiovascular diseases including coronary artery disease, ischemic stroke, and calcific aortic valve stenosis.
|
27761705 |
2016 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a), LDL cholesterol, and PCSK9 R46L genotype and diagnoses of aortic valve stenosis and myocardial infarction from national registries; lipoprotein(a) was measured from 49,617 individuals.
|
27218270 |
2016 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Human epidemiologic and genetic evidence using the Mendelian randomization approach in large-scale studies now strongly supports that elevated lipoprotein (a) [Lp(a)] is a causal risk factor for cardiovascular disease, that is, for myocardial infarction, atherosclerotic stenosis, and aortic valve stenosis.
|
27677946 |
2016 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis.
|
26685327 |
2016 |
|
Aortic Valve Stenosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The failure of statin trials in pre-existing aortic stenosis may be partially due to an increase in lipoprotein(a) and oxidized phospholipid levels caused by statins.
|
27205885 |
2016 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
APOE ε2 is a strong genetic determinant of low lipoprotein(a) concentrations but does not modify the causal association of lipoprotein(a) with myocardial infarction or aortic valve stenosis.
|
28651346 |
2017 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In particular, lipoprotein(a) [Lp(a)] and apolipoproteins (Apo) are associated with AS, but it is unknown whether these associations differ among phenotypes.
|
29246959 |
2017 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) is associated with adverse cardiovascular risk and is elevated in patients with aortic stenosis.
|
28704465 |
2017 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Prevalence of Lipoprotein(a) Measurement and Degree of Elevation Among 2710 Patients With Calcific Aortic Valve Stenosis in an Academic Echocardiography Laboratory Setting.
|
28068801 |
2017 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] is the strongest independent genetic risk factor for both myocardial infarction and aortic stenosis.
|
28059953 |
2017 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] is a proatherogenic lipoprotein associated with coronary heart disease, ischemic stroke, and more recently aortic stenosis and heart failure (HF).
|
28554015 |
2017 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lp(a) [lipoprotein (a)] is composed of apoB (apolipoprotein B) and apo(a) [apolipoprotein (a)] and is an independent risk factor for cardiovascular disease and aortic stenosis.
|
28729361 |
2017 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] has been classified as the most prevalent genetic risk factor for coronary artery disease and aortic valve stenosis.
|
30087087 |
2018 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] has been associated with AVS in recent genetic studies.
|
29614432 |
2018 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
New evidence supports a causal role for lipoprotein (a) in atherosclerotic cardiovascular disease and aortic valve stenosis.
|
29609758 |
2018 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, some biomarkers including plasma level of lipoprotein(a), F-sodium fluoride, brain natriuretic peptides and high-sensitivity cardiac troponin can be or are very close to be used for the clinical management of patients with aortic valve stenosis.
|
29194051 |
2018 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To replicate the association between LPA variants with AS and identify subgroups who are at higher risk of developing AS.
|
29128868 |
2018 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) (Lp(a)) is a causal risk factor for cardiovascular disorders including coronary heart disease and calcific aortic valve stenosis.
|
29852400 |
2018 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of Lipoprotein(a)-Levels in Patients ≥70 Years of Age With Versus Without Aortic Valve Stenosis.
|
29954600 |
2018 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A large number of epidemiological studies in ethnically diverse populations show that lipoprotein(a) [Lp(a)] levels above 30-50 mg/dL are significantly associated with calcific aortic valve stenosis, although less so in African Americans.
|
30616181 |
2019 |